Get notified when NUVL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNuvalent submits first NDA to FDA for neladalkib in ALK-positive lung cancer
Filed April 7, 2026 · Period ending April 7, 2026 · ~1 min read
Key Changes
-
high
Company filed New Drug Application with FDA for neladalkib to treat advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors
Item 8.01 verify on EDGAR → -
high
NDA submission marks first product candidate to reach regulatory filing stage for the company
Item 8.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GBCS 10-Q) is open in full — no account needed.
Partner
Trade NUVL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 23, 2026 11:32 AM